Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series - Summary - MDSpire

Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series

  • By

  • Avinash Chandu Nanwani

  • Jose Carlos De la Flor Merino

  • Elena Jiménez Mayor

  • Juan Daniel Díaz García

  • Celia Rodríguez Tudero

  • Arturo Villalobos Navarro

  • Esperanza Moral Berrio

  • Adriana Puente García

  • Jesus Hernández Vaquero

  • June 22, 2026

  • 0 min

Share

Objective:

To describe real-world experience with inclisiran in patients with stage G4–G5 CKD not receiving dialysis, focusing on lipid-lowering efficacy, renal outcomes, and treatment safety during follow-up.

Approach:
    Key Findings:
    • Median albuminuria reduced by 27.4%; however, this finding should not be attributed to inclisiran as all patients were on nephroprotective therapy.
    Interpretation:

    Limitations:
    • Small sample size of 10 patients limits generalizability.
    • Observational design may introduce bias.
    • Lack of a control group.
    Conclusion:

Original Source(s)

Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series

  • by Avinash Chandu Nanwani, Jose Carlos De la Flor Merino, Elena Jiménez Mayor, Juan Daniel Díaz García, Celia Rodríguez Tudero, Arturo Villalobos Navarro, Esperanza Moral Berrio, Adriana Puente García, Jesus Hernández Vaquero

  • June 22, 2026

Related Content

Mitochondrial DNA efflux as a potential amplifier of systemic inflammatory network rewiring in heart failure with preserved ejection fraction

Neighborhood Disinvestment and Racial Disparities in Early Hypertension Onset Among Women

Digital Health Intervention to Promote Lifelong Specialized Care in Adults With Congenital Heart Disease: Theory-Driven Community Co-Designed Study